Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors
Endocrine-Related Cancer · 2023
DOI: 10.1530/erc-22-0269 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2023. Verfasst von Tommaso Porcelli und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health, University of Naples 'Federico II', Naples, Italy. Hauptthemen laut MEDLINE: Iodide Peroxidase, Hypothyroidism. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 31 Literaturangaben.
Abstract (Originalsprache)
Treatment with tyrosine kinase inhibitors (TKIs) has been associated with alterations in circulating thyroid hormone levels, possibly related to perturbations in peripheral thyroid hormone metabolism. In this study, we evaluated the effect of the multi-kinase inhibitor vandetanib on the expression of the three deiodinase selenoenzymes, responsible for the thyroid hormone activation (type 1 and type 2 deiodinases) or for its inactivation (type 3 deiodinase). Here, we show that the multi-kinase inhibitor vandetanib determines a strong cell-specific downregulation of type 2 deiodinase (D2) expression and a significant reduction in D2 enzymatic activity. This occurs in the diffused population of fibro/adipogenic progenitors, which reside in different tissues – including the muscles – and normally express D2. Given the widespread diffusion of mesenchymal cells within the body, our results may explain at least partially the alterations in thyroid hormone levels that occur in vandetanib-treated patients. Our findings represent a step forward into the understanding of the mechanisms by which TKIs induce hypothyroidism and identify a resident cell population in which such an effect takes place.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health, University of Naples 'Federico II', Naples, Italy.
- Department of Clinical Medicine and Surgery, University of Naples 'Federico II', Naples, Italy.
- Department of Translational Medical Sciences, University of Naples 'Federico II', Naples, Italy.
- Department of Endocrine Oncology, Gustave Roussy and University Paris-Saclay, Villejuif, France.
- CEINGE Biotecnologie Avanzate Scarl, Naples, Italy.
ORCID-Profile: Tommaso Porcelli, Raffaele Ambrosio, Domenico Salvatore
Zitieren
APA
Porcelli, T., Ambrosio, R., De Stefano, M. A., Luongo, C., Terracciano, D., Miro, C., Dentice, M., Schlumberger, M., & Salvatore, D. (2023). Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors. Endocrine-Related Cancer. https://doi.org/10.1530/erc-22-0269
Vancouver
Porcelli T, Ambrosio R, De Stefano MA, Luongo C, Terracciano D, Miro C, et al. Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors. Endocrine-Related Cancer. 2023. doi:10.1530/erc-22-0269
BibTeX
@article{Porcelli2023,
author = {Porcelli, Tommaso and Ambrosio, Raffaele and De Stefano, Maria Angela and Luongo, Cristina and Terracciano, Daniela and Miro, Caterina and Dentice, Monica and Schlumberger, Martin and Salvatore, Domenico},
title = {Vandetanib downregulates type 2 deiodinase in fibro/adipogenic progenitors},
journal = {Endocrine-Related Cancer},
year = {2023},
doi = {10.1530/erc-22-0269}
}
EUVIMED